Candid-CL GEL

Quick links

Choose a section

Quick links to important sections

Advertisements

Candid-CL GEL

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Candid-CL GEL

Quick Facts

Property Description
Active Ingredients Clindamycin, Clotrimazole
Form Gel (Topical preparation)
Pharmacological Class Antibiotic and Antifungal Combination
Primary Action Dual antimicrobial targeting (Bacteria and Fungi)
Origin Synthetic/Semi-synthetic

What Type of Medicine is Candid-CL GEL? (Identity and Classification)

Candid-CL GEL is defined as a fixed-dose combination drug that functions as a topical anti-infective for localized skin application. This preparation utilizes two distinct, synthetic active components: the antibiotic Clindamycin and the antifungal agent Clotrimazole.

The two main components belong to different pharmacological classes. Clindamycin is classified as a Lincosamide antibiotic which targets susceptible bacteria. Conversely, Clotrimazole is categorized as an Imidazole antifungal, geared toward disrupting fungal structure. The strategic combination therapy offers a distinct advantage over single-agent products when an infection's etiology may involve both categories of pathogens.


Composition, Delivery, and Purpose

Candid-CL GEL is delivered in a specialized gel dosage form, a semisolid preparation specifically formulated for non-systemic, topical administration onto the skin. The gel base, which is typically hydrophilic, acts as the vehicle for delivering the active agents, ensuring their concentration is focused precisely on the application site.

This formulation is clinically recognized for facilitating easier application in sensitive or intertriginous areas where moisture retention from creams or ointments is undesirable. The fundamental purpose of this dual-action product is to offer comprehensive support against localized conditions, such as inflammatory skin concerns where bacterial colonization may complicate underlying fungal issues. By providing a broad-spectrum antimicrobial action that effectively targets both bacterial and fungal organisms, the preparation supports the resolution of mixed microbial etiology.

Regulatory References

  1. Clindamycin: MedlinePlus Drug Information
Advertisements

What side effects are possible with Candid-CL GEL?

Possible Side Effects and Safety Information

The official safety documentation for the topical combination of Clindamycin and Clotrimazole defines the drug's risk profile based on classifications established by government regulatory bodies. These profiles delineate potential adverse reactions by frequency and the body system affected, while also noting specific restrictions and serious risks.

Regulatory Safety Summary

Adverse reactions are primarily localized to the site of application, but the safety profile must also account for potential systemic effects from the antibiotic component, Clindamycin.

Classification Examples of Officially Documented Effects
Common Vaginal discharge, pruritus (itching), burning sensation, vulvovaginal discomfort.
Uncommon Headache, abdominal pain, diarrhea, nausea.
Serious / Rare Severe hypersensitivity reactions (e.g., anaphylaxis, angioedema), or antibiotic-associated colitis.

System-Organ Classes (SOCs) involved include Infections and Infestations, Immune System Disorders, Gastrointestinal Disorders, and Skin and Subcutaneous Tissue Disorders. The appearance of secondary infections or fungal overgrowth is documented as an exposure-related pattern.

Serious Adverse Reactions officially listed include the risk of Pseudomembranous Colitis/Antibiotic-Associated Colitis, a systemic risk associated with antibacterial agents like clindamycin, and severe systemic allergic responses.

Population-Specific Considerations restrict the use of this product. Use during the first trimester of pregnancy is generally not recommended. For lactation, a risk assessment must be made regarding the potential for adverse effects in the nursing infant. Safety and efficacy have not been established in patients under 12 years of age.

Safety Restrictions define that the product is contraindicated in individuals with a history of hypersensitivity to the active components or excipients, or with a history of pre-existing colitis conditions. The formulation also contains components that may temporarily deteriorate the reliability of latex or rubber products such as condoms and diaphragms.

Advertisements

Overdose and Emergency Response

The official overdose profile for this combination gel focuses primarily on the systemic risks associated with the absorption of its antibiotic component, Clindamycin. Acute overdosage resulting solely from excessive topical application is generally considered unlikely to lead to acute, life-threatening systemic effects. However, regulatory warnings confirm that systemic exposure to Clindamycin, even at low levels following topical use, carries the risk of severe gastrointestinal toxicity.

Documented overdose presentations that require caution include significant diarrhea, abdominal pain, and the occurrence of bloody stool. The most severe complication explicitly stated in regulatory documents is the development of pseudomembranous colitis (CDAD), which is a life-threatening manifestation that may result in patient death. This severe systemic risk is noted to be more prevalent in older patients.

Immediate medical attention is required, and the product must be discontinued without delay, if significant diarrhea or bloody stool is observed during or after use. A second critical concern is accidental oral ingestion of the topical gel; in this event, contact with a Poison Control Center or emergency medical services is required immediately. Management involves supportive and symptomatic treatment. Regulatory information emphasizes that no specific antidote is known, and that antiperistaltic agents must be strictly avoided as they may prolong or worsen Clindamycin-associated colitis.

Advertisements

Therapeutic Uses of Candid-CL GEL

What Candid-CL GEL Treats: Main Uses and Benefits

The Clindamycin and Clotrimazole combination product is relevant for use in gynecological infectious disease management, specifically targeting infections in the vaginal region that are often complex. The combination is generally indicated for bacterial and fungal infections susceptible to the product's components.

This localized anti-infective is used for conditions where symptoms point toward mixed microbial etiology, including presentations of Bacterial Vaginosis (BV) and Vulvovaginal Candidiasis (VVC). The primary benefit is providing broad anti-infective support, which assists with infection clearance and helps ease related discomfort.

The treatment is applied to address the disruptive symptom cluster of localized discomfort, including intense vulvovaginal itching, burning, and soreness. By addressing the underlying microbial cause, it also helps with the normalization of discharge characteristics and assisting with the reduction of offensive smell. This targeted relief directly at the site of inflammation contributes to easing the overall symptom load of acute manifestations.

“This approach is relevant when symptoms are driven by microbial overgrowth and helps manage the acute symptomatic phases that interfere with daily comfort.”

Quick Fact: Relief for Vulvovaginal Discomfort

Property Description
Primary Therapeutic Context Mixed vaginal infections (Bacterial and Fungal)
Symptom Management Focus Itching, burning, abnormal discharge, and malodor
Key Patient Benefit Supports infection clearance and assists with maintaining functional stability
Clinical Scenario Used in situations requiring comprehensive symptomatic and anti-infective assistance
Advertisements

Eligibility and Restrictions for Use

The eligibility profile for Candid-CL GEL (Clindamycin/Clotrimazole) is strictly defined by regulatory documents, distinguishing between permitted, conditional, and contraindicated populations.

Populations Contraindicated (Must Not Use)

Use is strictly contraindicated for individuals with a history of hypersensitivity to Clindamycin, Clotrimazole, Lincomycin, or any component of the formulation. The product is also prohibited for patients with a history of specific inflammatory bowel conditions, including regional enteritis, ulcerative colitis, or any history of antibiotic-associated colitis.

Age-Group and Life Stage Restrictions

The safety and effectiveness of the gel have not been established in children younger than 12 years of age, and use is generally restricted prior to the onset of menstruation. Clinical data is considered insufficient to establish a differential response in subjects aged 65 and over.

Pregnancy and Lactation Status

  • First Trimester Pregnancy: Use is conditional and only recommended if clearly needed.
  • Second and Third Trimester Pregnancy: Use is generally permitted.
  • Lactation: Use is restricted, requiring a decision to either discontinue nursing or discontinue the drug.

Regulatory documents also note no data available to establish specific use limitations in patients with significant hepatic or renal impairment.

Advertisements

What should I know about interactions with other medicines?

Interactions with other Medicines and Products

Official regulatory documentation identifies specific substance categories and medicinal products that interact with the active components of Candid-CL GEL (Clindamycin and Clotrimazole), focusing on functional outcomes and systemic risk.

Documented Interaction Patterns

The Clindamycin component carries a pharmacodynamic potentiation risk, as it is documented to enhance the action of Neuromuscular Blocking Agents (NMBAs) used in anesthesia, such as Atracurium and Tubocurarine, due to its intrinsic neuromuscular blocking properties. Additionally, its use may enhance the effects of the anticoagulant Warfarin, a pharmacokinetic consequence that may lead to an increased International Normalized Ratio (INR) requiring monitoring.

Restrictions and Antagonism

Interaction Type Interacting Substance Official Regulatory Outcome
Physical/Functional Latex/Rubber Products (e.g., Condoms, Diaphragms) Product components weaken the material, leading to functional failure. Use is restricted during and after treatment.
Antagonism Polyene Antifungal Agents (e.g., Amphotericin B, Nystatin) Clotrimazole's activity is documented to be depressed by co-administration.
Metabolic Tacrolimus and Sirolimus (Immunosuppressants) Potential for Clotrimazole's minimal systemic absorption to cause an increase in plasma concentration via CYP inhibition.

Concurrent use of Clindamycin with antiperistaltic agents may prolong or worsen antibiotic-associated colitis. Strong CYP3A4 inducers (e.g., Rifampicin) may decrease Clindamycin exposure, while inhibitors (e.g., Ketoconazole) may increase it.

Advertisements

Mechanism of Action

The mechanism of Candid-CL GEL is defined by the dual, non-competitive actions of its components, facilitating the simultaneous addressing of two distinct microbial classes. Clindamycin engages the mechanistic domain of inhibiting bacterial translation. The molecule achieves this by binding directly to the 50S ribosomal subunit, which is essential for assembling proteins. This interaction halts the elongation of peptide chains, leading to a bacteriostatic action that prevents further microbial proliferation. The molecular cascade results in the localized reduction of viable bacterial load, which lessens the pathogenic stimulus.

Concurrently, Clotrimazole acts within the domain focused on disrupting fungal cell integrity. It achieves this by inhibiting the enzyme lanosterol 14-alpha-demethylase (CYP51), which is crucial for creating ergosterol, the primary lipid in the fungal membrane. The resulting depletion of ergosterol and the accumulation of toxic precursors lead to increased membrane permeability and subsequent structural compromise, exhibiting fungistatic and fungicidal actions.

Advertisements

Dosage and Administration Information

How to Use Candid-CL GEL: Administration Guidelines

This section details the usage patterns for the Clindamycin and Clotrimazole combination product.


Administration Scope

Instruction Usage Principle
Route of Administration The product is restricted to intravaginal use only and is not intended for oral, dermal, or ophthalmic application.
Dosing Schedule The standard adult regimen requires the administration of one single-use pre-filled applicator (typically 5 grams of gel/cream) or one vaginal suppository.
Frequency and Timing Administration is scheduled once daily (q.d.). To maximize retention and efficacy, the application is designated to occur at bedtime (qHS).
Course Duration The regimen is a fixed course, typically requiring treatment for 3 or 7 consecutive days, depending on the specific formulation being administered.
Missed Dose If a daily dose is missed, it is applied as soon as it is remembered. However, if the time is near for the next scheduled dose, the missed dose is generally skipped to avoid double dosing, and the regular schedule is resumed.

Procedural Structure and Use Constraints

The usage protocol is defined by procedural and time-based constraints. The full dose must be administered using the disposable applicator provided, and the entire prescribed number of days must be completed to adhere to the regimen. Furthermore, the constraints on administration include avoiding the use of latex or rubber barrier contraceptives during and for a specified period (e.g., 5 to 7 days) following the treatment course, as components in the base may compromise their integrity.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Candid-CL GEL


Evidence for Use in Mixed Bacterial and Fungal Vaginosis

Research was evaluated in patients with conditions associated with acute or disruptive episodes, where diagnostic patterns indicated a potential mixed bacterial and fungal microbial etiology. Studies were conducted during periods of increased symptom activity and utilized Randomized Controlled Trials (RCTs) alongside comparative open-label studies. This research was applied in studies examining patient-reported experiences in non-pregnant adult women diagnosed with this type of condition.

Studies monitored outcomes related to physical discomfort and monitored both clinical status (such as the presence of physical signs) and microbiological status (pathogen presence). Trials also monitored patient-reported outcomes describing perceived discomfort and the assessment of symptom intensity over defined time intervals. Research describes patterns observed in the studies over defined time intervals, with follow-up durations typically extending up to two weeks.

However, certain uncertainties remain in the research landscape. Many reports describe trials using non-gel formulations, such as vaginal suppositories or creams, which means there is limited information specifically for the gel preparation. Comparative evidence is limited for trials directly comparing the combination product against single-agent therapies for pure bacterial or pure fungal infections.


Evidence for Vulvovaginal Candidiasis (VVC) and Symptom Relief

The evidence base for the antifungal component, Clotrimazole, includes Systematic Reviews and Meta-analyses. This research contributes to the broader evidence landscape for VVC, which is a condition involving periods of heightened symptoms. Trials were observed in research contexts involving fluctuating or unstable symptoms in adult women with a confirmed VVC diagnosis.

Research explored outcomes related to physical discomfort and outcomes describing episodic or acute changes. Studies reported how symptoms evolved in the observed populations and measured the mycological status (absence of yeast). While certainty remains low regarding the combination’s specific use in monoinfection, the evidence level for the single-agent Clotrimazole component, based on systematic reviews, is supported by high-level evidence.


Key Uncertainties and Research Gaps

One key research limitation is that the results apply mainly to the study conditions, with limited information for long-term outcomes regarding the sustained effect of treatment. Furthermore, there is a lack of certainty regarding the generalizability of some findings because the sample sizes were modest in various studies, and comparative evidence is limited against key monotherapies. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References

  1. A Clinical Experience to Assess Safety and Efficacy of Fixed Dose Combination of Clindamycin and Clotrimazole in the Treatment of Patients With Mixed Bacterial and Fungal Vaginosis
  2. Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Candid-CL GEL (FAQ)


Q: Does Candid-CL GEL only work for internal vaginal infections, or can it be used for external vulval itching?

Official administration instructions specify this medicine is strictly for intravaginal use only. Its application is restricted to the vagina, and it is not indicated for application to other areas, such as the eyes, mouth, nose, or external skin, including for vulval itching. The product's safety and effectiveness are tied to its intended route of administration.


Q: What are the main symptoms or signs that this combination gel is prescribed to address?

This medication’s stated purpose is to manage infections that result in abnormal vaginal discharge. According to official sources, it is also prescribed to relieve associated symptoms such as itching, a burning sensation, and local irritation.


Q: What are the recognized signs of an allergic reaction to Candid-CL GEL that are mentioned in official documents?

Official documentation notes the risk of serious side effects, including severe hypersensitivity reactions like anaphylaxis or angioedema (swelling). Guidance advises attention to any signs of irritation or discomfort that worsen or persist during treatment, as these warrant professional assessment.


Q: Is it possible for Candid-CL GEL to cause pain or cramping in the lower pelvic area?

Yes, regulatory safety summaries document that pelvic pain and pelvic cramps are listed as possible side effects. Other related gastrointestinal effects, such as abdominal pain, have also been reported with the use of this medicine.


Q: What is the recommended period of time to avoid using latex condoms or diaphragms after the last application of Candid-CL GEL?

The base components in the gel can weaken latex or rubber products. Use of these barrier contraceptives is restricted during treatment and for a specified period after the final dose, which is often cited as being between 3 and 7 days.


Q: How does the gel formulation of Candid-CL GEL compare to other forms like vaginal suppositories in terms of absorption?

The formulation is designed for non-systemic, topical administration, meaning it works locally at the application site. Official data shows that only a minimal amount of the antibiotic component, about 5%, is typically absorbed into the bloodstream. This results in minimal systemic absorption compared to medicines taken orally.


Q: Is Candid-CL GEL appropriate for individuals who have a weakened immune system, such as those with HIV?

Official information indicates that the presence of certain medical problems, including having a weakened immune system, may affect the use of this medicine. Therefore, professional consultation is advised for individuals in this category.


Q: Is it still possible to use Candid-CL GEL if a patient is currently experiencing their menstrual period?

Available patient information indicates that the treatment course may generally be continued even if the patient begins their menstrual period. Adherence to any specific instructions provided by the prescribing professional is key.


Q: Can individuals with diabetes use Candid-CL GEL without special precaution?

The presence of other medical conditions, such as diabetes, may influence how this medicine is used. Informing a healthcare provider of the diabetes condition is noted in the guidance before starting the course of treatment.


Q: What information is available on the safety of using Candid-CL GEL when trying to conceive?

Reproduction studies conducted in animals using the clindamycin component of the gel have shown no evidence of impaired fertility. Nevertheless, the medicine's use is subject to professional assessment to determine if it is clearly needed.


Q: How quickly should a patient typically expect to see an improvement in symptoms after starting Candid-CL GEL?

The full treatment course must be completed for the best outcome. The guidance suggests informing a healthcare provider if symptoms do not improve within 3 days of starting the medicine, indicating that a lack of early improvement may warrant review.


Q: How long does the effect of Candid-CL GEL usually last in the body after a single dose?

The duration of effect for this topical medication is typically localized. Reports indicate that the medicine's activity lasts for an average of 4 to 6 hours following a single application.


Q: What official recommendation is given if common side effects like local irritation do not improve or worsen?

Guidance indicates that if minor side effects such as local burning, stinging, or irritation do not go away or if they become worse, discontinuation of use and communication with a healthcare professional are warranted.


Q: What is the guidance if the gel is accidentally exposed to the eyes or mouth?

The procedure requires that, in cases of accidental exposure of the medicine to the eyes or mouth, the affected area is immediately washed off thoroughly with plenty of water.


Q: Do products like douches or tampons interfere with how Candid-CL GEL works during treatment?

Yes, official guidance restricts the use of other vaginal products, such as tampons or douches, during the course of treatment. These products can potentially interfere with the medication’s effectiveness.


Q: Are there any known or potential interactions between Candid-CL GEL and alcohol consumption?

Due to the minimal systemic absorption of the topical gel, the risk of interactions between the medicine and alcohol consumption is generally considered unlikely. However, professional consultation is generally advised before consumption.


Q: What is the official recommendation regarding engaging in sexual intercourse while using Candid-CL GEL?

Official documentation suggests avoiding sexual intercourse while using the medicine. This is intended to help prevent the possible spread of the infection and ensure that the treatment remains effective.


Q: Can using vaginal products like spermicides or scented soaps affect the treatment with Candid-CL GEL?

Yes, official information restricts the use of other vaginal products during treatment, which includes both spermicides and scented soaps. These products may disrupt the local environment or interfere with the medication’s intended action.


Q: Why is it advised to avoid using other vaginal products during the treatment period?

The primary reason for restricting the use of products like douches and tampons is that they can interfere with the medicine's effectiveness. This interference can potentially reduce the concentration of the active ingredients at the site of infection.


Q: Is Candid-CL GEL categorized as a prescription-only medicine?

Based on regulatory documentation, this product is typically categorized as a HUMAN PRESCRIPTION DRUG. This means it requires a prescription from a licensed healthcare professional for use.


Q: Is Candid-CL GEL a medication that is considered to be habit-forming or have addictive properties?

Official drug safety information indicates that this medicine does not cause addiction and is not associated with habit-forming properties.


Q: Can Candid-CL GEL be used for conditions other than vaginal infections, such as general skin fungus?

The product is classified as a topical anti-infective and is indicated for use in conditions such as bacterial vaginosis and vulvovaginal candidiasis (vaginal yeast infection). Its use is restricted to the specific conditions indicated in the regulatory documents.


Q: Does official information address whether Candid-CL GEL has any effect on long-term fertility?

While the gel's effects on long-term fertility are not specifically detailed for the combination product, studies on the clindamycin component in animals revealed no evidence of impaired fertility.


Q: Are there any specific patient populations where using the applicator is discouraged?

The safety and effectiveness of the medication have not been established in children under 12 years of age. Use is also generally restricted prior to the onset of menstruation, implying that the procedural application is unsuitable for this population.

Advertisements

How should Candid-CL GEL be stored and disposed of?

Storage and Disposal Requirements

Official regulatory guidelines establish mandatory conditions for storing Candid-CL GEL to ensure its stability and potency. The product must be stored below 30 C and should be protected from both freezing and light exposure.

Storage Conditions

  • Temperature and Handling: Store below 30 C; do not freeze the gel.
  • Protection: Keep the container tightly closed and store in the original carton, protected from light.
  • Safety: The medication must be kept out of the reach and sight of children.

Disposal of Unused Product

Unused or expired Candid-CL GEL must be managed according to specific pharmaceutical waste procedures. It must not be disposed of via wastewater or household trash.

Patients should consult a pharmacist for guidance on how to properly discard the medicine in compliance with all local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Candid-CL GEL found in:

A-Z Index: